Better still, Auroras stock is poised to deliver even more gains to investors in the years ahead. Heres why.
Estimates for the size of the global cannabis market continue to grow larger. Investment firm Cowen now expects worldwide cannabis sales to reach $75 billion by 2030, up from a previous forecast of $50 billion by 2026. Bank of America, meanwhile, believes the marijuana market could one day reach $166 billion in annual sales. And Canopy Growth (NYSE:CGC) Co-CEO Bruce Linton, perhaps unsurprisingly, has the most optimistic prediction of all: He believes cannabis could eventually disrupt markets totaling $500 billion.
While no one knows for sure just how large the cannabis market will ultimately become, one thing is certain: Products derived from marijuana and hemp are enjoying rapidly increasing demand across the world. People are using marijuana and cannabidiol (CBD) to treat a variety of ailments, both medically and recreationally. As such, cannabis has the potential to disrupt massive industries such as alcohol, tobacco, and pharmaceuticals.
Having built a formidable position in marijuana production, Aurora Cannabis stands to benefit more than perhaps any other company from this booming demand for cannabis.
Aurora Cannabis (ACB) is expected to report sales of ~577 million Canadian dollars—243% year-over-year growth. However, the growth isnt expected to translate into profits in the near term.
Of all the publicly traded marijuana producers, Aurora Cannabis has the highest peak production capacity by far. Thanks to its purchases of MedReleaf, CanniMed, ICC Labs, and a host of other acquisitions, Aurora is on track to produce more than 625,000 kilograms of cannabis annually by 2020. Among Auroras rivals, only Canopy Growth can even claim 500,000 kilograms in peak production potential.
As the largest marijuana producer, Aurora Cannabis will enjoy scale advantages over its smaller rivals. It should generate higher profit margins, as it will be able to spread its costs over a larger revenue base. It will also be in a stronger position to sign lucrative supply deals with wholesalers and governments, particularly in international markets, where Aurora has a leading presence.
Additionally, Auroras scale should allow it to become one of the marijuana industrys lowest-cost producers. In turn, Aurora should be better able to withstand falling marijuana prices better than its smaller competitors. Moreover, lower prices could even help to strengthen Auroras competitive position. Thats because when supply finally catches up with demand, there will likely be a period of industry consolidation as smaller, higher-cost producers struggle to survive. Aurora will likely emerge stronger during this period, particularly if it finds itself in position to acquire some of the smaller producers at a discount.
All told, in a largely commodity-based industry such as marijuana, low-cost production is paramount. Auroras massive scale should serve it well in this regard.
When a business purchases another company, it typically needs to pay a substantial premium in order to entice its shareholders to accept the deal. But while this can produce significant short-term gains for the acquired companys investors, it can come at the expense of potentially far larger long-term gains. This is perhaps one the reasons Aurora Cannabis has resisted selling a large equity stake to a bigger business, as its rivals Canopy Growth and Cronos Group have done.
Alcohol giant Constellation Brands invested more than $4 billion in Canopy Growth in exchange for a 38% stake in the Canadian marijuana producer, as well as warrants that would allow it to up its stake to 50% in the future. Meanwhile, tobacco titan Altria Group purchased a 45% stake in Cronos Group — along with warrants that give it the right to boost its stake to 55% — for $1.8 billion.
These deals have provided Canopy Growth and Cronos Group with much-needed capital to fund their expansion projects. But theyve potentially come at the expense of remaining independent. Altria can acquire a majority — and therefore, controlling — share of Cronos Group if it chooses to exercise its warrants. Constellation Brands is widely expected to acquire at least half of Canopy Growth — and perhaps all of the companys remaining shares — should the marijuana producer continue to perform well in the coming years.
In contrast to Canopy and Cronos, Aurora Cannabis has yet to strike a major deal with a larger company, and it reportedly does not intend to do so. Billionaire investor Nelson Peltz — whom Aurora brought onboard as a strategic advisor in March — believes Aurora should remain independent. As my colleague Keith Speights notes, rather than sell a large stake to one company, Peltz recommends that Aurora forge strategic partnerships with multiple businesses across several industries — thereby aligning itself with more allies.
Perhaps most importantly, by remaining independent, Aurora Cannabis is positioning itself — and its shareholders — to capture a larger share of the companys value creation in the years ahead. As such, investors seeking to profit from the long-term growth of the cannabis market are likely best served by buying shares in Aurora Cannabis rather than Canopy Growth or Cronos Group.
Investing.com – Cannabis stocks fell sharply on Friday after the Federal Drug Administration said it was still uncertain how safe cannabinoid found in marijuana is for human consumption.
Tilray (NASDAQ:TLRY) fell 1.4%, while Aurora Cannabis (TSX:ACB), Cronos Group (NASDAQ:CRON) and Canopy Growth Corp (NYSE:CGC) fell around 4%.
The FDA got its first public hearing on cannabidiol, one of the most common chemical compounds found in marijuana, underway, with a host of cannabis companies seeking to sway the FDA to permit the sale of cannabis-derived dietary supplements and foods products.
But before the arm-wringing has even begun, the agency warned there is still much to find out about the risks of cannabis food products.
In prepared remarks, Acting Commissioner Ned Sharpless said there are “real risks associated with (THC and CBD) and critical questions remain about the safety of their widespread use in foods and dietary supplements.”
While medical marijuana has been permitted in a number of states to treat various ailments, including severe pain and nausea, cannabinoid is not allowed in dietary supplements or foods.
Friday’s hearing is unlikely to prove anything more than a fact-finding mission for the agency, and many say this is just the first step in a long battle for cannabis companies attempts to get their marijuana-infused munchies legalized.
We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.